Previous 10 | Next 10 |
Gainers: Taiwan Liposome (TLC) +36%. Ocular Therapeutix (OCUL) +21%. LogicBio Therapeutics (LOGC) +11%. American Well (AMWL) +11%. Tiziana Life Sciences (TLSA) +11%.Losers: Enlivex Therapeutics (ENLV) -12%. Aytu BioScience (AYTU) -12%. Xtant Medical (XTNT) -11%. ARCA bioph...
Thinly traded micro cap Taiwan Liposome Company ([[TLC]] +31.7%) jumps on an 8x surge in volume in reaction to regulatory sign-offs in Australia and Taiwan to launch a Phase 1 clinical trial evaluating inhalable liposomal hydroxychloroquine in 30 healthy volunteers.Results will inform subsequ...
Taiwan Liposome (TLC) +89% after company secures Australian and Taiwan approval to initiate trial of inhaled malaria drug for COVID-19.Ocean Power Technologies (OPTT) +47%.Sunworks (SUNW) +45% on announcing $10M in Q3 project wins.Urban Tea (MYT) +31%.Hill International (H...
Taiwan Liposome (TLC) has received ethical and scientific approval from the Bellberry Human Research Ethics Committee ((HREC)) in Australia for its Phase I clinical trial of TLC19 Hydroxychloroquine Liposome Inhalation Suspension for COVID-19.The HREC reviews clinical trial proposals to ...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 07, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the receipt of ethical and scientific a...
Gainers: Genfit (GNFT) +15%, Evogene (EVGN) +13%, Marinus Pharmaceuticals (MRNS) +11%, Endo International (ENDP) +8%, Happiness Biotech Group (HAPP) +7%.Losers: Rite Aid (RAD) -10%, Cellect Biotechnology (APOP) -8%, Kaleido...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that President Mr. George Yeh and Chie...
Ampio Pharmaceuticals Inc. ( AMPE ) has had a long road to FDA approval for its osteoarthritis drug called Ampion. It's been 9 years and 5 clinical trials in the making, and they are in their final push for approval. There is clear evidence suggestive of approval for Ampion in osteoarthritis o...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 11, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that George Yeh, President of TLC, wil...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company’s President Mr...
News, Short Squeeze, Breakout and More Instantly...
Taiwan Liposome Company Ltd. Company Name:
TLC Stock Symbol:
NASDAQ Market:
Taiwan Liposome Company Ltd. Website:
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Sele...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreem...